Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD.
Galapagos NV (GLPG) and MorphoSys (MPSYY) announced the presentation of more detailed results of the Phase 1 study with the investigational IL-17C antibody MOR106 in atopic dermatitis patients at the American Academy of Dermatology Annual Meeting 2018. Initial study data were reported in September 2017. In the study, MOR106 showed first signs of activity and durable responses and was generally well tolerated in AD patients. In the multiple ascending doses part, 25 patients received four infusions once weekly of either MOR106 or placebo in a 3:1 ratio. Patients were followed for 10 weeks after the end of the treatment period. In the MAD part in AD patients reported at AAD 2018, all adverse drug reactions observed were mild-to-moderate and transient in nature. No serious adverse events and no infusion-related reactions were recorded. MOR106 exhibited a favorable pharmacokinetics profile with dose-dependent exposure. At the highest dose level of MOR106, in 83% of patients an improvement of at least 50% in signs and extent of AD, as measured by EASI-50, was recorded at week 4. The onset of activity occurred within two to four weeks, depending on the dose administered. MOR106 was generated using MorphoSys' Ylanthia antibody platform and is based on a target discovered by Galapagos. IL-17C is a cytokine which has been related to dermal inflammation and has been shown to be distinct from other members of the IL-17 cytokine family. MOR106 is the first publically known human monoclonal antibody against IL-17C in clinical development worldwide. MOR106 is an investigational drug and its safety and efficacy are yet to be established. It is expected that Phase 2 development with MOR106 will be initiated in the first half of 2018.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 17, 2018|
|Previous Article:||Lockheed Martin receives Freedom-variant FFG conceptual design contract.|
|Next Article:||FX Update: The dollar traded generally firmer.|